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Introduction
The cancer stem cell hypothesis proposes that the cells of cancers are organized in hierarchies initiated and maintained by a cancer stem cell (CSC). The existence of such a hierarchy in tumor propagation was first described in hematopoietic malignancies [3, 28] , but has later been extended to a variety of other cancers. The strongest support for this model comes from transplantation assays in immunodeficient mice where only a subpopulation of the cells in the tumor bulk can initiate and maintain the tumor upon serial grafting. Despite substantial evidence from preclinical studies, the relevance of this model to human disease is uncertain. Two studies have now identified a leukemic stem cell (LSC) signature of gene expression associated with acute myeloid leukemia and it has shown that this signature correlates with the clinical outcome [9, 13] . These studies have established LSCs as significant in clinical disease. A direct comparison of the gene expression profiles of LSCs and hematopoietic stem cells (HSCs) grown under identical conditions, has resulted in new insight into critical pathways regulating CSCs in leukemia [33] .
Besides a paucity of clinical evidence, testing the cancer stem cell model is challenging due to the lack of markers that consistently define CSCs. For example, LSCs were initially believed to be restricted to the CD34+ CD38-population, but have later been shown to be present in both the CD34-and CD34+CD38+ populations [9, 47, 48] . Such heterogeneity has also been shown in solid cancers. In glioblastoma (GBM), the best characterized surface marker is CD133 (prominin-1), but CD133
− cells also initiate tumors upon xenografting [42, 52] and it has been suggested that the true GBM stem cell (GSC) resides in the CD133 − population [6] . Thus, surface marker-sorted CSC populations cannot be universally defined and functional confirmation of CSC activity using well-validated tumor initiation assays is required. GBM is both the most common and the most malignant brain tumor. It is invariably lethal with a median survival of less than 10 months in unselected patient populations [18] . The existence of CSCs in brain tumors was first suggested following the isolation of clonogenic stem cell-like spheres from human GBM tissue [21] . Serum-free, growth factor-enriched culturing conditions, developed to isolate and expand somatic neural stem cells [44] , have been shown to be a robust method for enrichment of stem-like cells from a range of organs and malignancies [43] . Here, we have used this technique to directly compare GSCs to ahNSCs harvested from the subventricular zone. ahNSCs can differentiate into the three neural lineages [22] , including functional neurons [34] that develop synaptic networks [34, 35] . Tumor biopsies cultured under identical conditions maintain genotype, phenotype and the ability to form invasive tumors [10, 29, 51] . Sphere growth rate and the ability to form spheres under these conditions is related to tumor grade [49] and is an independent prognostic factor within the glioblastoma group [27] .
Global gene expression studies of GSC populations have led to the identification of subgroups [17, 32] but have not identified which pathways regulate cancer stem cell functions and do not address the question of how to specifically target GSCs. Here we directly compare the gene expression from functionally validated, enriched fractions of CSCs from a solid tumor to its closest functional non-tumorigenic, adult cell population. We identify the genes, pathways and networks shared between ahNSCs and GSCs, and those specific to the oncogenic phenotype of GSCs. We highlight significant differences found in the expression of classical stem cell signaling pathways, in particular dysregulation of the Wnt-pathway through SFRP1, a Wnt-signaling inhibitor downregulated in GSCs. Cancer stem cell-specific genes have been validated and we show that their expression predicts clinical outcome in GBM patients.
Materials and methods

Fresh human biopsy specimens and spheroid cultures
Biopsy specimens were obtained from informed and consenting patients, and the tissue harvesting was approved by the Norwegian National Committee for Medical Research Ethics. Histopathological diagnosis and grading were performed by neuropathologists according to the World Health organization classification [25] . ahNSC cultures were established from ventricular wall biopsies of 5 patients operated on for medically intractable temporal lobe epilepsy (mean age 42, range . GSC cultures were established from tumor biopsies from nine patients with histopathologically verified glioblastoma (mean age 61, range 48-71). The cells were isolated mechanically and enzymatically and further cultured in serum free medium enriching for stem cells as described earlier [51] . For dissociation of brain tissue into single cells, Trypsin-EDTA was substituted by papain (Worthington Biochemical Corporation).
RNA isolation
Total RNA from spheres was isolated using Qiazol and the RNeasy Micro Kit (Qiagen GmbH, Hilden, Germany). The concentration of each RNA sample was determined by using a Nanodrop spectrophotometer and analyzed for quality using an Agilent 2100 Bioanalyzer with the RNA Nano Assay. Only RNA samples with a RIN value 48 were included for further analysis.
Microarray hybridization and analysis of microarray data RNA of each sample was reverse transcribed and amplified using the NanoAmp RT-IVT Labeling Kit (Applied Biosystems). The resulting cRNA (10 mg) was fragmented and hybridized to Applied Biosystems Human Genome Survey Microarray V2.0 (Applied Biosystems) according to the manufacturer's protocol Analysis and statistics were done using J-Express (Molmine), R (version 2.11.1) and Bioconductor. External data files were extracted from the GEO database. For details regarding bioinformatic analysis see supplemental information.
Quantitative real-time PCR
Total RNA was reverse transcribed using the High Capacity cDNA synthesis kit (Qiagen, Germany) and followed by qPCR using predesigned TaqMan gene expression assays and reagents (Applied Biosystems). Both the standard curve method and the 2 −ΔΔCT method were used to analyze the data. For details regarding TaqMan gene expression assays see supplementary  information and supplementary Table S7 . 
SFRP1 stimulation
GSCs and ahNSCs were passaged into single cells and seeded in 96 well plates (Sarstedt AG & Co, Germany) at a density of 500 cells per well in stem cell enriching media. SFRP1 was added daily in three different concentrations (100, 400, and 800 ng/ml) for 2 weeks. Each assay included 6 replicates of each treatment and was repeated 3 times in total. Spheres in individual wells were inspected and counted manually using a microscope and an automatic colony counter (Gelcount, Oxford Optronix). Cell proliferation was measured as change in total level of nucleic acids as compared to untreated control cells using CyQUANT according to the manufacturer's instructions (Molecular Probes, Invitrogen).
Accession Numbers
Microarray data have been submitted to the Gene Expression Omnibus (GSE31262) and the online resource "The Stem Cell Discovery Engine" [19] .
Results
Obtaining and characterizing samples ahNSCs and GSCs were cultivated as free floating spheres from five normal subventricular zone and nine primary GBM tissue biopsies, respectively. All cell cultures formed secondary spheres. Both ahNSCs and GSCs maintained the ability to proliferate, selfrenew and differentiate in vitro, but only the GSCs gave rise to tumors upon orthotopic transplantation to SCID-mice [49] . GSCs were able to initiate tumor formation upon serial transplantation, and maintained their genome, global expression profile and ability to differentiate after in vitro cultivation [51] . All but one GBM tissue sample (G3) was IDH1 mutation negative in line with the frequency of IDH1 mutations in primary GBMs [24] .
GSCs are more heterogeneous than ahNSCs and represent different subtypes of GBMs
Hierarchical clustering based on the pair-wise correlation of global gene expression profiles separated the GSC and ahNSC samples, indicating that the transcriptional programs of individual GSC cultures differ from ahNSCs (Fig. 1A) . There was generally a much greater heterogeneity across the GSCs than across the ahNSCs (0.81 vs. 0.47; average square of differences to the mean per probe). Two outliers were identified in the tumor group (G2 and G3) ( Fig. 1C & D) . Of these, G3 showed a pronounced difference in behavior compared to the other GSC cultures. In addition to a more limited differentiation ability in vitro, it also formed a compact noninvasive tumor bulk containing spindle-like cells when transplanted to SCID mice [51] . Since G3 obviously had lost its ability to mimic the invasive nature of GBMs, it was excluded from further gene-expression analysis. Investigation of GBM heterogeneity in tissue biopsies suggests the existence of molecular subgroups [12, 40, 50] . The Cancer Genome Atlas (TCGA), being the most significant study, describes four such subgroups of GBMs: the proneural, neural, classical and mesenchymal subtype. The subtypes are identified dependent on the level of enrichment of a total of 840 genes (210 genes per class). To explore if such subtypes were present among our population of GSCs, we calculated the enrichment of these subtypes individually for every sample. The expression score was calculated as the mean expression of the genes in the signature using the rank-normalized gene expression scores (z-score). 173 samples from the original TCGAstudy were included as positive controls. While all ahNSCs showed a homogeneous correlation with the neural subtype, seven of the GSC cultures were enriched in genes representing either the classical, proneural or mesenchymal subtype. Two of the GSC cultures (including the outlier G3) did not show enrichment of any particular subgroup (supplementary Fig. S1 and supplementary Table S1 ). We further classified our samples according to the less well established GSC classification by Lottaz et al. [32] . This classification contains only two groups, (1) mesenchymal and (2) proneural. Hierarchical clustering according to their 24-gene signature identified one sample as belonging to their type 1 (G9) while the other 7 belonged to type 2 ( Supplementary Fig. S1 ). The outlier (G3) clustered separately from the others and was generally much less enriched in signature genes.
GSCs and ahNSCs share common stem-and lineage-related markers
To determine the common molecular phenotype of ahNSCs and GSCs, we directly compared the expression of known "stemness" genes as well as markers of the three principal cellular components of the nervous system -neurons (DCX, NCAM1, TUBB3, and MAP2), astrocytes (CD44, VIM, GFAP, and SLC1A3) and oligodendrocytes (OLIG2, CNP, CA2, and CSPG4). GSCs and ahNSCs expressed approximately the same levels of stemness markers, such as nestin (NES), SSEA1 (FUT4), OCT4 (POU5F1), BMI1 (PCGF4), β1-integrin (ITGB1) and SOX2. There was no significant difference in the expression of markers for neurons, astrocytes and oligodendrocytes ( Fig. 2A) . CD133 (PROM1) and MELK were   226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285   286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345 significantly upregulated in GSCs ( Fig. 2A) . Using immunofluorescence we investigated the expression of selected markers (NES, GFAP, MELK, CXCR4, BMI1 and SOX2) at the protein level. All markers were similarly expressed, except for SOX2 which was overexpressed in GSCs (Fig. 2B) .
A GSC expression index correlates with patient survival
Recently, it was shown for the first time that an LSC gene signature predicts patient survival in human leukemia [9, 14] , providing the impetus for an analogous investigation in GBM. Using the Rank Product algorithm [5] at a stringent threshold (0.1% false discovery rate (FDR)), we identified 179 genes being significantly upregulated in GSCs compared to ahNSCs. An additional filter was applied (fold change45; coefficient of variationo30 in GSC samples; average log2o1 for ahNSCs) to isolate a 30-gene signature which was highly overexpressed in all GSC samples studied ( Fig. 3A and Table S2 ). This GSC signature included MELK, a gene known to regulate self-renewal and proliferation of both neural stem cells and GSCs in vitro and in vivo [37, 38] . Interestingly, a literature search for each signature gene identified eleven of these as downstream targets of or related to the Notch-, Hedgehog-or Wnt-pathways (Table S2) . The signature was further projected onto a network of protein association data, including protein interactions, co-expression, co-localization and domain similarity [53] (Fig. 3B) . The network   346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405   406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465 Log-2 value Log-2 value G4  G7  G6  G5  G2  G8  G9  G1  G3  H2  H1  H4  H3  H5  H5 H3 H4 H1  G3 G1 G9 G8 G2 G5 G6 G7 G4  H2  H2 H1 H4 H3 H5 G3 G5 G7 G6 G4 G2 G9 G1 G8   G3   G2 analysis demonstrated that a high proportion of the signature genes codes for proteins that are known to physically interact with each other, strongly suggesting that these play a coordinated role in the regulation on GSCs. Their enriched set of biological processes involve proliferation and cell-division (gene ontology analysis, Table S2 ).
We calculated a GSC expression index for each array from a publically available dataset containing gene expression levels for normal brain tissue, and low-and high grade gliomas [45] , based on the summed Z-scores of the 30 genes in the GSC signature. This index correlated to an increasing grade of malignancy ( Fig. 3C and Table S3 ).
The value of this index in predicting clinical outcome was assessed using two additional publicly available gene expression data-sets of high-grade gliomas [12, 40] . In each study, patients were stratified into two groups according to the expression of the 466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525   526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585   G9  G5  N1 N2 N3 N4 N5 G1 G8  G4  G6 G7 G2   PCGF4   CXCR4   SOX2   ITGB1 SHCBP1  DBF4  CDCA1  CDC2  CCNB1  MAD2L1  CENPF  CRISPLD1  B3GNT5  SEPT11  FARP1  LBH  LPL  BRRN1  TOP2A  KIAA0101  UHRF1  IMP-3  TPX2  MELK  KIF2C  CDCA5  CEP55  HCAP-G  TEAD2  CDC45L  ARHGAP11A  RAD51 GSC signature using K-means clustering. In both datasets we identified a significant correlation between the GSC expression index and survival, with a median survival of 124 vs. 62 weeks (low and high signature, respectively) and 684 vs. 224 days (Fig. 4A & B and Table S4 ). For both datasets the two clusters included both WHO glioma grade III and GBM tumors. The fraction of grade IV tumors was higher in the group with high GSC expression signature; 85% vs. 60% and 97% vs. 64% in the two datasets (high and low signature, respectively). Interestingly, our GSC expression index showed a better ability to discern patient survival than a gene signature recently developed based on unsupervised gene clustering in the tumor bulk by Li et al. [30] ; having a median survival of 97 vs. 65 weeks (low and high signature, respectively) and 412 vs. 341 days (Table S4 ). This strongly suggests that our 30-gene signature is clinically relevant and provides evidence that the CSC model is applicable to human GBM.
ATAD2
Genes upregulated in GSCs correlate with the expression profiles of ESCs and iPSCs
To determine the extent to which the GSC signature is expressed across a wide range of cell types, a summary score was calculated for the expression of the GSC signature (5% FDR) across a large proportion of the publicly available gene expression arrays in the Gene Expression Omnibus ($160,000 arrays). Fitting the distribution of these scores to a mixture-model allowed for the calculation of a   706  707  708  709  710  711  712  713  714  715  716  717  718  719  720  721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765   766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824 825 probability of expression of the GSC signature in each array ( Fig. 4C ; upper panel). Within this dataset, a collection of embryonic stem cells (ESCs) and inducible pluripotent stem cells (iPSCs) arrays were manually curated to highlight the expression of the GSC signature in these arrays relative to the full GEO data. A set of fibroblast arrays was used as an additional control. The genes in the signature was found to be highly expressed within the group of 281 pluripotent arrays of ESCs and iPSCs (p¼0.042) ( Fig. 4C ; lower panel and Table  S5 ), with a mean expression level higher than 96% of all arrays profiled. Calculated as individual groups, iPSCs (p¼0.033) showed a higher expression of this signature than ESCs (p¼ 0.062). These findings support the hypothesis that GSCs share gene expression programs with pluripotent cell types known for their tendency to generate tumors when transplanted in preclinical models of neurodegenerative disease.
Dysregulation of pathways and networks in GSCs
The functional characteristics that distinguish GSCs from ahNSCs were determined by identifying signaling pathways and regulatory networks enriched in the differentially expressed gene signature. Two strategies were used, providing different levels of sensitivity and specificity. Firstly, using a differential gene expression analysis applying the Rank Product algorithm we identified 423 upregulated and 414 downregulated genes at 1% FDR ( Fig. 1B and Table S6 ). The enrichment of canonical pathways in this gene list was determined using the hypergeometric distribution, based on pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Wikipathways [41] . Twenty-four pathways were found to be significantly enriched (p-valueo0.01), with the cell cycle (p-value¼ 1.42E-13) and the Wnt pathway (p-value¼3.75E-5) being the most significant ( Fig. 5 and Table S6 ). Secondly we performed an additional analysis with a greater emphasis on sensitivity rather than specificity using the Comparative Marker Selection suite [16] . This identified 1713 upregulated and 2544 downregulated genes (po0.05) (Table S6) . Their enrichment in the Canonical Pathways collections of the Molecular Signatures Database (MSigDB) were assessed by the hypergeometric distribution. The most significantly enriched upregulated genes were related to the cell cycle (Cell Cycle Combined, DNA Replication Reactome, G1 To S1 Cell Cycle Reactome) and to cell signaling pathways (TNF, MAPK, NFKβ, mTOR, NOTCH and p53/ apoptosis) ( Fig. S2 and Table S6 ). Several pathways related to cellto-cell interaction (Tight Junction, Axon guidance) and neuronal function (calcium regulation, GABA pathway) were downregulated in GSCs compared to their normal counterparts (Fig. S2 and Table  S6) .
Detailed information about the experiments and the resulting gene sets generated are available for pathway comparison with other stem and cancer and stem cell datasets in the online resource "The Stem Cell Discovery Engine" [20] .
Stem cell pathways -the Wnt-pathway is more dysregulated than hedgehog and notch
Earlier studies have suggested that inhibition of the Hedgehog-or Notch-signaling pathway reduces the tumorigenicity of GSCs [7, 11] . Interestingly, although we found that the Hedgehog pathway and activated transcriptional targets of the Notch pathway were enriched in GSCs (p ¼8.47 Â 10 −4 and p¼ 1.79 Â 10 −3 respectively), the Wnt-signaling pathway was the most significantly dysregulated (p¼ 3.75 Â 10 −5 ). A gene-level analysis of each of these pathways and their downstream targets was conducted to provide a detailed understanding of their role in GSCs (Fig. 6 ). Both cell types expressed very low levels of the Hedgehog pathway-associated Shh-ligand and the transcription factors GLI1 and GLI2. GSCs, however, expressed significantly higher levels of the membrane receptor smoothened (SMO) and the transcription factor GLI3 (Fig. 6 ). Significant upregulation of downstream targets (p ¼0.02) supported the importance of the Hedgehogpathway in GSCs.
The core genes necessary for Notch-signaling (KEGG) were present above background levels in both cell types. The Notch 2 receptor and the transcription factor Hes1 were significantly upregulated in GSCs (Fig. 6) . Analysis of downstream targets gave ambiguous results as both activated and repressed targets of Notch were enriched in GSCs.   826  827  828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885   886  887  888  889  890  891  892  893  894  895  896  897  898  899  900  901  902  903  904  905  906  907  908  909  910  911  912  913  914  915  916  917  918  919  920  921  922  923  924  925  926  927  928  929  930  931  932  933  934  935  936  937  938  939  940  941  942  943  944  945 Fig. 5 -Network view of pathways being dysregulated in GSCs: The pathway analysis was based on the gene list identified by the Rank Product Algorithm (1% FDR) and was done using wikipathways and netpath. The significance of each pathway is reflected as indicated by the color code. Gene overlap between pathways is indicated by the intensity of the lines connecting the different pathways.
Analysis of the Wnt-pathway showed that core genes were expressed in both cell types, but a number of the pathway members were differentially regulated. The membrane receptors FZD3, 5 and 7 were upregulated in GSCs compared to ahNSCs, while soluble Frizzled related protein 1 (SFRP1) was significantly downregulated. The set of activated downstream targets of the Wnt pathway were also enriched in the set of GSC expressed genes (p¼ 0.002).
Wnt-pathway dysregulation could be confirmed at gene expression-and protein level
To confirm the finding that the Wnt pathway plays a significant role in GBM/GSCs we performed a qPCR screen of more than 90 Wnt-related genes (Fig. 6 & supplementary Table S7 ). Excluding weakly expressed genes (Ct 430), we identified upregulation of WNT7A and FZD 2, 3 and 7 and downregulation of WNT5B. The downregulation of SFRP1 and upregulation of SFRP4 was confirmed. LEF1 and TCL7F, transcription factors involved in Wnt downstream signaling, were significantly upregulated.
The activity of β-catenin depends on its phosphorylation state. In cells not exposed to Wnt signals, β-catenin levels are kept low as a result of phosphorylation by GSK-3. When cells are exposed to Wnt signals, GSK-3 is trapped in another complex and does not phosphorylate β-catenin anymore. Only this unphosphorylated, stabilized form of the protein can enter the nucleus to interact with transcription factors. To investigate the activity of β-catenin in GSCs and ahNSCs, we quantified both total and active (dephosphorylated) β-catenin by western blot. While total β-catenin was present in both cell types, its active form was only present in GSCs (Fig. 7E) . To further establish the activation status of Wntsignaling in GSCs, we used immunofluorescence combined with confocal microscopy to determine the subcellular localization of β-catenin. This showed the presence of active β-catenin in the nucleus of GSCs (Fig. 7A, upper panel) . These data further support the finding that Wnt-signaling is upregulated in GSCs.
Wnt-pathway inhibition reduces proliferation and sphere forming capacity in GSCs
GSCs proliferate and form spheres much more efficiently than ahNSCs [49] , and the ability to form such spheres is a prognostic predictor for patients with GBM [27] . Our data indicated both downregulation of the naturally occurring Wnt antagonist SFRP1 and an upregulation of Wnt pathway ligands, receptors and transcription factors in GSCs. Therefore, we investigated the effect of SFRP1 on GSCs and ahNSCs in culture. Recombinant SFRP1 was added daily in three different concentrations to the GSC and ahNSC cultures for two weeks. This treatment led to a significant and dose-dependent reduction of both proliferation and sphere formation in GSCs by as much as 70% and 50%, respectively (Fig. 7B & C) . In contrast, SFRP1-stimulation did not interfere with proliferation of ahNSC (Fig. 7D) . SFRP1 treated spheres were also smaller than non-treated (Fig. 7A, right) and β-catenin was located in the cytoplasm and the cell membrane, instead of in the nucleus (Fig. 7A, lower panel) . This indicates that loss of naturally occurring Wnt-inhibition through downregulation of SFRP1 is important for GSCs' ability to proliferate and self-renew.
Discussion
We have developed the first internally consistent experimental and molecular reference between GSCs and ahNSCs using functionally validated sphere-forming cells. Sphere-forming conditions enriched   1066  1067  1068  1069  1070  1071  1072  1073  1074  1075  1076  1077  1078  1079  1080  1081  1082  1083  1084  1085  1086  1087  1088  1089  1090  1091  1092  1093  1094  1095  1096  1097  1098  1099  1100  1101  1102  1103  1104  1105  1106  1107  1108  1109  1110  1111  1112  1113  1114  1115  1116  1117  1118  1119  1120  1121  1122  1123  1124  1125   1126  1127  1128  1129  1130  1131  1132  1133  1134  1135  1136  1137  1138  1139  1140  1141  1142  1143  1144  1145  1146  1147  1148  1149  1150  1151  1152  1153  1154  1155  1156  1157  1158  1159  1160  1161  1162  1163  1164  1165  1166  1167  1168  1169  1170  1171  1172  1173  1174  1175  1176  1177  1178  1179  1180  1181  1182  1183  1184 for stem cells but result in a heterogeneous mixture of stem-and progenitor cells. There is, however, evidence that comparison of closely related but distinguishable cell fractions can reveal stem cell specific gene expression, even though the actual stem cell frequency is relatively low. For example, many genes identified from enriched but not purified HSC fractions have subsequently been shown to have HSC-specific function [15, 39] . Similarly, in this study we identified MELK and EHZ2, both of which have earlier been suggested to regulate GSC self-renewal and tumor initiating capacity [37, 38, 46] . Our strategy of directly comparing expression patterns of GSCs to ahNSCs, as opposed to non-stem cell populations, has enhanced our ability to identify genes and pathways that are disrupted at the stem cell level in GBM.
While there is substantial preclinical evidence that certain cancers are organized in cell hierarchies initiated and maintained by a CSC, the relevance of this model in human disease is still uncertain. Two independent groups compared transcriptional programs of functionally validated LSCs and HSCs, identified a LSC gene signature, and showed that high expression of this signature was associated with adverse clinical outcome in human leukemia [9, 14] . These studies were first to provide substantial support for the CSC hypothesis in leukemia from a clinical perspective. Using a similar strategy we have here identified a gene expression signature that exists in GSCs, but not in ahNSCs, that correlates to survival in independent data sets. This indicates that GSCs are of clinical importance in GBM.
Recently, Engström et al. compared four glioma stem cell lines with two human fetal neural lines [8] . In contrast to both our study and the study of Majeti et al. on LSCs, both of which used early passage normal stem cells from relevant normal human tissue, Engström el al. used cells that were (1) fetal and (2) grown as adherent cell lines [32] . This result in a different cell type and accordingly, a very different profile from what we found when comparing GSCs to ahNSCs. While Engström et al. identified 739 genes being differentially regulated within a significance level of 10% FDR, a similar cut-off in our study generated a list of 3264 differentially regulated genes. The two lists had 247 genes in common, but none of these were among our most significant genes (179 genes, FDR 0.1%). Consequently, the extracted core signatures capturing the major gene expression alterations in the respective studies differ. This was also reflected in the results from pathway analysis identifying the top-most enriched KEGG-pathways. While our study identified the cell cycle and the Wnt pathway, Engström et al. identified cytokine-cytokine receptor interaction and the chemokine signaling pathway as the most dysregulated pathways. ECM-receptor interaction was the only pathway shared between the two studies. Despite differences in the cell types used and the signatures identified, the results from Engström et al. are in consistent with a clinical relevance of the CSC hypothesis in solid tumors.
We found that GSC cultures were more heterogeneous than ahNSCs. While our GSC cultures covered a spectrum of TCGA subtypes, all five ahNSCs correlated with the neural subtype. Not all GSC cultures showed enrichment of a particular subgroup. The TCGA sub-classification [50] was, however, developed using tumor bulk tissue and may not be optimal for stem cell enriched cell types. Although significant, the expression scores of subtypegenes in GSCs were not as high as those found in tissue samples. Subtyping of the samples according to Lottaz et al. identified one sample (G9) as their type I with a mesenchymal profile similar to ahNSCs. G9 was also identified as mesenchymal according to TCGA. Lottaz showed that their type II corresponds with a proneural phenotype, but did not investigate enrichment of subtypes other than mesenchymal and proneural. Our samples identified as Lottaz type II, were enriched in genes of either the proneural or classical TCGA subtypes. In order to get a full overview of the tumor initiating cell/stem cell population and significantly establish subtypes of GSCs, it will be important to cultivate cells from a larger number of patients.
We also found that genes up-regulated in GSCs were highly expressed in both ESCs and iPSCs as compared to the other arrays in the GEO database. This is in keeping with the tendency of these cell types to form tumors following transplantation in preclinical models of neurodegenerative disease repair [4] . The identified correlation of GSCs with iPSCs was higher than the correlation of GSCs with ESCs, supporting recent literature indicating that iPSCs are likely to be more tumorigenic than ESCs [2] .
Pathway analysis identified that GSCs express a gene signature typically associated with migrating cells and the interaction of stem cells with their niche: axon guidance, adherens junction, focal adhesion, regulation of actin cytoskeleton and leukocyte transendothelial migration. With the exception of axon guidance, these pathways were also identified as the top-most dysregulated pathways in leukemic cells in the only other study directly comparing cancer stem cells to somatic adult stem cells [33] . Thus, CSCs of different origin may have common features. A growing number of studies on stem cell related cancers are being performed. It is important to be able to determine the underlying molecular phenotype of CSCs, in particular, to determine if there are common molecular events between cancer stem cell studies. To facilitate such comparisons, we have made the data generated by this study available within a specialized resource for stem-and cancer stem cell signatures that is structured to facilitate discovery of common and unique pathway utilization between signatures [20] .
The Wnt-and Hedgehog-pathway genes, as well as Notchregulated targets showed altered expression in GSCs. These three pathways are important regulators of adult NSCs [1, 26, 31] , and Hedgehog-and Notch-signaling have additionally been suggested to be involved in regulating GSCs [7, 11] . Here, we have identified and characterized canonical Wnt-pathway dysregulation in GSCs.
Within the Wnt-pathway we identified significant downregulation of SFRP1 and upregulation of FZD receptors (FZD 2, 3 and 7) in GSCs. Active β-catenin was only present in GSCs. A primary trait of GSCs is that they form spheres and proliferate much more efficiently than ahNSCs [49] . This ability to form spheres correlates with clinical outcome [27] . We found that re-establishing SFRP1-inhibition in GSCs decreases both proliferation and sphere forming ability. In contrast, SFRP1-stimulation did not interfere with proliferation of ahNSCs. These findings are in keeping with effects observed earlier in normal HSCs [36] and ESCs [23] .
Our study provides evidence substantiating the clinical relevance of CSCs in solid tumors and gives critical insights into the similarities and differences between adult normal and malignant stem cell populations. The results may be used for the development of targeted therapies and as tools for assessing the impact of therapy on the GSC population.
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